India, Jan. 31 -- A large section of people in China trusts traditional medicines. Popularised as a mainstream healthcare category, these drugs have built a $50 Bn opportunity in the country's $80 Bn pharma market. But, the situation is starkly different in India, where age-old ayurveda controls merely a fourth of a $40 Bn market for pharma products, despite its deep cultural roots.

Various reasons, spanning from an aging populace with a median age of 40.6 years to its innate preference for natural alternatives, backed this surge in Traditional Chinese Medicines (TCM). But, what stood out most strikingly was a lack of rigorous, evidence-based scientific research in India. Ameve Sharma spotted a dearth of modern, science-backed ayurvedic ...